Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of ...

Merck MRK decided to discontinue two clinical development programs, namely KeyVibe and KEYFORM, which are evaluating its ...

Merck & Co.’s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of ...

Merck, known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYFORM -007 trial evaluating the investigational fixed-dose combination of favezelimab, Merck’ s ...

Favezelimab was designed to prevent a protein called LAG-3 from binding to certain molecules on tumor cells. This activates the body's immune response and can reduce tumor growth.

On Wednesday, Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for ...

Merck to discontinue vibostolimab and favezelimab programs after futility in Phase 3 trials for NSCLC and Hodgkin lymphoma. FDA to decide on Merck's RSV antibody, clesrovimab, by June 10, 2025 ...

Merck, known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an ...

Merck: Favezelimab/Keytruda Combo Study Misses Goal in Colorectal Cancer Provided by Dow Jones Sep 25, 2024, 11:20:00 AM. By Colin Kellaher .

RAHWAY, N.J., September 25, 2024--Update on KEYFORM-007 Trial Evaluating Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1+ MSS mCRC ...

On Wednesday, Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of favezelimab and pembrolizumab versus the standard of care for ...